Mingyu Pharmaceutical Resubmits IPO Application to Hong Kong Exchanges With 11 Pipeline Candidates

According to Hong Kong Exchanges and Clearing (HKEX) disclosure on July 8, Mingyu Pharmaceutical Co., Ltd.-B resubmitted its initial public offering application to the HKEX Main Board, with Morgan Stanley, BofA Securities, and CITIC Securities serving as joint sponsors. Founded in 2018, the biotech company specializes in integrated oncology, focusing on antibody-drug conjugates (ADC) and advanced immunotherapy development. As of July 1, 2026, its pipeline comprises 11 candidate products, including two core assets.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments